CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CX-2029’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CX-2029 overview

CX-2029 is under development for the treatment of solid tumors including squamous non-small cell lung cancer (sqNSCLC), squamous head and neck cancer (sqHNSCC), esophageal cancer, gastroesophageal (GE) junction cancers, lymphomas including diffuse large B-cell lymphoma, adenoid cystic carcinoma of parotid gland, colorectal cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, malignant pleural mesothelioma, non-small cell lung carcinoma, non-small cell lung carcinoma, ovarian cancer, oncocytic carcinoma of parotid gland, ocular melanoma pancreatic cancer, prostate cancer, perivascular epithelioid cell tumor, soft tissue sarcoma, bladder cancer, thyroid carcinoma, thymoma or thymic cancers, renal cell cancer and hepatocellular cancer. It is administered intravenously. The drug candidate is developed based on probody platform. The drug candidate acts by targeting CD71 protein (transferrin receptor).  It was also under development for the treatment breast cancer.  It was also under development for Burkitt lymphoma.

CytomX Therapeutics overview

Cytomx Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. it develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, pro body drug conjugate, and T-cell bispecific. Its products CX-072, is a PD-L1 targeting Probody therapeutic for the treatment of cancer; CX-2009, currently under is a CD166-directed PDC for the treatment of cancer; BMS-986249, under Phase is a CTLA-4-directed Probody therapeutic intended for the treatment of solid cancers; CX-2029, under is a PDC directed against CD71 intended for the treatment of B-cell lymphoma; CX-188, is a PD-1-targeting Probody therapeutic. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.

For a complete picture of CX-2029’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.